Lipoprotein apheresis: an update

被引:30
作者
Julius, Ulrich [1 ]
Fischer, Sabine [1 ]
Schatz, Ulrike [1 ]
Hohenstein, Bernd [1 ]
Bornstein, Stefan R. [1 ]
机构
[1] Univ Hosp Carl Gustav Carus Dresden, Dept Internal Med 3, D-01307 Dresden, Germany
关键词
cardiovascular events; HDL cholesterol; LDL cholesterol; lipoprotein(a); lipoprotein apheresis; statins; triglycerides; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; C-REACTIVE PROTEIN; LDL-APHERESIS; LIPID-APHERESIS; WHOLE-BLOOD; CARDIOVASCULAR EVENTS; PLASMA-CONCENTRATIONS; VASCULAR-DISEASE;
D O I
10.2217/clp.13.68
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since the 1980s, several lipoprotein apheresis methods that eliminate atherogenic lipoproteins (LDL and lipoprotein(a) [Lp(a)]) have been developed. These methods are based on the following principles: precipitation, adsorption and filtration. In Dresden (Germany), we started to perform extracorporeal treatment in 1990; in the 1980s we were working as a lipidologic center and saw patients dying due to severe atherosclerotic diseases. At present, 80 patients are being treated with six different methods at the Apheresis center at the University Hospital Dresden. The effectiveness of these methods with respect to lowering of LDL cholesterol and Lp(a) is somewhat different. The number of patients with high Lp(a) levels and with severe atherosclerotic complications has increased steadily since 2008. Several studies have shown a high effectiveness for apheresis treatment in these patients. In the future, new drugs (e.g., lomitapide, mipomersen or PCSK9 inhibitors) will probably modify the position of apheresis in the therapeutic regimen.
引用
收藏
页码:693 / 705
页数:13
相关论文
共 90 条
[1]  
[Anonymous], 2008, BANZ
[2]   HEPARIN EXTRACORPOREAL LDL PRECIPITATION (HELP) - AN EFFECTIVE APHERESIS PROCEDURE FOR LOWERING LP(A) LEVELS [J].
ARMSTRONG, VW ;
SCHUFFWERNER, P ;
EISENHAUER, T ;
HELMHOLD, M ;
STIX, M ;
SEIDEL, D .
CHEMISTRY AND PHYSICS OF LIPIDS, 1994, 67-8 :315-321
[3]   Lipoprotein(a) levels and risk of future coronary heart disease [J].
Bennet, Anna ;
Di Angelantonio, Ernanuele ;
Erqou, Sebhat ;
Eiriksdottir, Gudny ;
Sigurdsson, Gunnar ;
Woodward, Mark ;
Rumley, Ann ;
Lowe, Gordon D. O. ;
Danesh, John ;
Gudnason, Vilmundur .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (06) :598-608
[4]   Hyperlipoproteinemia(a): Clinical significance and treatment options [J].
Berthold, Heiner K. ;
Gouni-Berthold, Ioanna .
ATHEROSCLEROSIS SUPPLEMENTS, 2013, 14 (01) :1-5
[5]   Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity? [J].
Berthold, Heiner K. ;
Descamps, Olivier S. ;
Gouni-Berthold, Ioanna .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2013, 43 (01) :108-112
[6]   26 Years of LDL-Apheresis: A review of experience [J].
Borberg, H. .
TRANSFUSION AND APHERESIS SCIENCE, 2009, 41 (01) :49-59
[7]   Improvement of hemorheology by DALI apheresis: Acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients [J].
Bosch, T ;
Wendler, T ;
Jaeger, BR ;
Samtleben, W .
THERAPEUTIC APHERESIS, 2001, 5 (05) :372-376
[8]   Low-Density Lipoprotein Apheresis Decreases Ferritin, Transferrin and Vitamin B12, Which May Cause Anemia in Serially Treated Patients [J].
Bramlage, Carsten P. ;
Armstrong, VictorW ;
Zapf, Antonia ;
Bramlage, Peter ;
Mueller, Gerhard A. ;
Koziolek, Michael J. .
THERAPEUTIC APHERESIS AND DIALYSIS, 2010, 14 (02) :136-142
[9]  
Bundesministerium f?r Gesundheit (German Ministry of Health), 2003, BANZ, V123, P14486
[10]   The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway [J].
Catapano, A. L. ;
Papadopoulos, N. .
ATHEROSCLEROSIS, 2013, 228 (01) :18-28